The rise of adenoviral Covid-19 vaccines highlights the potential of companies using similar technology in other fields like cancer or gene therapy. However, complex challenges remain, such as circumventing immunity to adenoviral treatments.
Earlier this month, Johnson & Johnson’s candidate became the first single-shot Covid-19 vaccine to get the EMA green light. The vaccine is based on a genetically modified adenovirus, as are others in the market such as the Russian Sputnik V and the AstraZeneca vaccine. Alongside cutting-edge messenger RNA (mRNA) technology, adenovirus-based vaccines are proving one of the dominant technology platforms for vaccinating the world against Covid-19.
Adenoviruses make up a diverse family of DNA viruses that typically cause mild respiratory symptoms in humans such as the common cold. They have been used as delivery vectors for vaccines and gene therapies for decades. These vectors offer numerous advantages to genetic engineers, including that they are easily modified with foreign genes and typically cause mild to no symptoms.
“The unique advantages of adenoviruses that have enabled the rapid development and rollout of these vaccines will only increase in global relevance over the foreseeable future,
The post Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology appeared first on Labiotech.eu.
Published on Thu, 25 Mar 2021 15:53:25 +0000 and brought to you by Apptigent PowerTools